Syrjälä H, Schildt R, Räisäinen S
National Public Health Institute, Oulu, Finland.
Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):68-70. doi: 10.1007/BF01964409.
The in vitro susceptibility of ten strains of Francisella tularensis to four fluoroquinolones (ciprofloxacin, norfloxacin, ofloxacin and pefloxacin) was investigated by determining the MBCs of these quinolones. The results were as follows (mean +/- SE): ciprofloxacin 0.13 +/- 0.03 mg/l, norfloxacin 0.24 +/- 0.07 mg/l, ofloxacin 2.16 +/- 0.78 mg/l and pefloxacin 0.51 +/- 0.50 mg/l. These concentrations can be achieved in clinical practice. In addition, four tularemia patients were treated with an oral regimen of 750 mg ciprofloxacin b.i.d. and one patient with norfloxacin 400 mg b.i.d. The fever experienced by these volunteers vanished within a couple of days and they were able to resume normal work one week after receiving the antibiotics without any relapses later. These in vitro and in vivo results show that orally administered fluoroquinolones are promising antimicrobial agents for the treatment of human tularemia.
通过测定四种氟喹诺酮类药物(环丙沙星、诺氟沙星、氧氟沙星和培氟沙星)的最低杀菌浓度(MBC),研究了十株土拉弗朗西斯菌对这四种氟喹诺酮类药物的体外敏感性。结果如下(平均值±标准误):环丙沙星0.13±0.03mg/L,诺氟沙星0.24±0.07mg/L,氧氟沙星2.16±0.78mg/L,培氟沙星0.51±0.50mg/L。这些浓度在临床实践中能够达到。此外,四名兔热病患者接受了每日两次口服750mg环丙沙星的治疗方案,一名患者接受了每日两次口服400mg诺氟沙星的治疗方案。这些患者经历的发热在几天内消退,并且在接受抗生素治疗一周后能够恢复正常工作,之后没有任何复发。这些体外和体内结果表明,口服氟喹诺酮类药物是治疗人类兔热病有前景的抗菌药物。